You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

combination treatment,

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Multiple Myeloma in Relapse Trial (Belantamab mafodotin, Venetoclax)

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Belantamab mafodotin, Venetoclax
  • (no location specified)
May 10, 2023

Oral Leukoplakia Trial in Minneapolis (pioglitazone-metformin)

Not yet recruiting
  • Oral Leukoplakia
  • Minneapolis, Minnesota
    University of Minnesota
Feb 4, 2023

Melanoma Trial in Aurora (VESANOID, Ipilimumab)

Active, not recruiting
Has Results
  • Melanoma
  • Aurora, Colorado
    University of Colorado Hospital
Sep 7, 2022

Muscle Weakness Trial in Gilbert, River Bluff, West Columbia (BTL-899; HPM-6000UF Treatments)

Completed
  • Muscle Weakness
  • BTL-899; HPM-6000UF Treatments
  • Gilbert, Arizona
  • +2 more
Jan 26, 2023

Acromegaly Trial in Los Angeles (Pegvisomant, Octreotide LAR, Lanreotide)

Terminated
Has Results
  • Acromegaly
  • Los Angeles, California
    Cedars-Sinai Medical Center
Dec 12, 2022

Amlodipine/Atorvastatin/Perindopril Single Pill Combination

Not yet recruiting
  • Arterial Hypertension
  • HTN
  • Amlodipine 5 mg + atorvastatin 10 mg + perindopril arginine 5 mg
  • +2 more
  • (no location specified)
Mar 1, 2023

Cervical Cancer, CIN2, CIN3 Trial in Westdene (5 Fluorouracil (5 FU) Cream, Placebo)

Not yet recruiting
  • Cervical Cancer
  • +4 more
  • 5 Fluorouracil (5 FU) Cream
  • Placebo
  • Westdene, Johannesburg, South Africa
    Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospita
Nov 30, 2022

Objective Response, Overall Survival Trial in Beijing (VIA combination treatment)

Completed
  • Objective Response
  • Overall Survival
  • VIA combination treatment
  • Beijing, China
    Peking University People's Hospital
Dec 9, 2022

Pelvic Floor Disorders Trial in Fort Collins, Macon, Chestnut Hill (BTL-899; HPM-6000UF Treatments)

Active, not recruiting
  • Pelvic Floor Disorders
  • BTL-899; HPM-6000UF Treatments
  • Fort Collins, Colorado
  • +2 more
Sep 8, 2022

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

Acne, Postinflammatory Hyperpigmentation Trial in Dubai (anti-acne dermocosmetic)

Completed
  • Acne
  • Postinflammatory Hyperpigmentation
  • anti-acne dermocosmetic
  • Dubai, United Arab Emirates
    L'Oreal
Oct 31, 2022

Recurrent Thyroid Cancer Trial in Baltimore (Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive

Recruiting
  • Recurrent Thyroid Cancer
  • Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)
  • Baltimore, Maryland
    The Johns Hopkins SKCCC
May 25, 2022

Photoaging Trial in Pflugerville (LaseMD Laser, Sciton Laser, Phyto A+ Brightening Treatment)

Not yet recruiting
  • Photoaging
  • LaseMD Laser
  • +2 more
  • Pflugerville, Texas
    Austin Institute for Clinical Research, Inc.
Oct 13, 2023

SSG/Allopurinol Combination Treatment in Ethiopia

Recruiting
  • Cutaneous Leishmaniasis
  • Sodium Stibogluconate with allopurinol
  • Dessie, Ethiopia
    Boru Meda Hospital
Mar 7, 2022

Nasopharyngeal Tumors Trial (The combination treatment of anlotinib, penpulimab and capecitabine.)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • The combination treatment of anlotinib, penpulimab and capecitabine.
  • (no location specified)
Apr 10, 2023

Overactive Bladder, Overactive Bladder Syndrome Trial in Maribor (mirabegron 50 mg daily, Extracorporeal magnetic innervation

Completed
  • Overactive Bladder
  • Overactive Bladder Syndrome
  • mirabegron 50 mg daily
  • +2 more
  • Maribor, Slovenia
    University Medical Centre Maribor
Nov 8, 2023

Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)

Recruiting
  • Ovarian Cancer Recurrent
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Science and Peking Un
Aug 23, 2023

Thyroid Cancer Trial (20 mg Famitinib & 1200 mg Adebrelimab)

Not yet recruiting
  • Thyroid Cancer
  • 20 mg Famitinib & 1200 mg Adebrelimab
  • (no location specified)
Nov 26, 2023

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,

Not yet recruiting
  • Colorectal Cancer
  • HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
  • HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
  • (no location specified)
Jul 13, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Gastric Cancer Stage IIIB-IIIC Trial in Shanghai (Pembrolizumab + SOX)

Recruiting
  • Gastric Cancer Stage IIIB-IIIC
  • Pembrolizumab + SOX
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 7, 2023

Glioblastoma, Recurrent Glioblastoma, GBM Trial in Boston (MN-166, Temozolomide)

Active, not recruiting
  • Glioblastoma
  • +3 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Nov 16, 2022

Endometrial Carcinoma Trial in Sohag (Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin)

Not yet recruiting
  • Endometrial Carcinoma
  • Sohag, Egypt
    Sohag university Hospital
Oct 25, 2023

Osteoradionecrosis, Osteoradionecrosis of Jaw, Osteoradionecrosis of the Mandible Trial (modified PENTOCLO (mPENTOCLO), sham

Not yet recruiting
  • Osteoradionecrosis
  • +2 more
  • modified PENTOCLO (mPENTOCLO)
  • sham mPENTOCLO
  • (no location specified)
Sep 19, 2023